Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s12012-020-09621-2 http://scihub22266oqcxt.onion/10.1007/s12012-020-09621-2 33387252!7778391!33387252     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33387252&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 225.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Cardiovasc+Toxicol 2021 ; 21 (4): 314-321 Nephropedia Template TP {{tp|p=33387252|t=2021. QTc Prolongation in COVID-19 Patients Using Chloroquine |pdf=|usr=}}{{33387252}} gab.com Text QTc Prolongation in COVID-19 Patients Using Chloroquine JO: Cardiovasc Toxicol http://www.kidney.de/pget.php?&tw=1&pmid=33387252 #FOAvip Chloroquine is used in the treatment of patients with COVID-19 infection, although there is no substantial evidence for a beneficial effect. Chloroquine is known to prolong the QRS and QTc interval on the ECG. To assess the effect of chloroquine on QRS and QTc intervals in COVID-19 patients, we included all inpatients treated with chloroquine for COVID-19 in the Spaarne Gasthuis (Haarlem/Hoofddorp, the Netherlands) and had an ECG performed both in the 72 h before and during or at least 48 h after treatment. We analyzed the (change in) QRS and QTc interval using the one-sample t-test. Of the 106 patients treated with chloroquine, 70 met the inclusion criteria. The average change in QRS interval was 6.0 ms (95% CI 3.3-8.7) and the average change in QTc interval was 32.6 ms (95% CI 24.9-40.2) corrected with the Bazett's formula and 38.1 ms (95% CI 30.4-45.9) corrected with the Fridericia's formula. In 19 of the 70 patients (27%), the QTc interval was above 500 ms after start of chloroquine treatment or the change in QTc interval was more than 60 ms. A heart rate above 90 bpm, renal dysfunction, and a QTc interval below 450 ms were risk factors for QTc interval prolongation. Chloroquine prolongs the QTc interval in a substantial number of patients, potentially causing rhythm disturbances. Since there is no substantial evidence for a beneficial effect of chloroquine, these results discourage its use in COVID-19 patients. Twit Text FOAVip QTc Prolongation in COVID-19 Patients Using Chloroquine ????Cardiovasc Toxicol http://www.kidney.de/pget.php?&tw=1&pmid=33387252 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33387252 #FOAvip English Wikipedia <ref>{{Cite pmid|33387252}}</ref> QTc Prolongation in COVID-19 Patients Using Chloroquine #MMPMID33387252 Becker ML; Snijders D; van Gemeren CW; Kingma HJ; van Lelyveld SFL; Giezen TJ Cardiovasc Toxicol 2021[Apr]; 21 (4): 314-321 PMID33387252show ga Chloroquine is used in the treatment of patients with COVID-19 infection, although there is no substantial evidence for a beneficial effect. Chloroquine is known to prolong the QRS and QTc interval on the ECG. To assess the effect of chloroquine on QRS and QTc intervals in COVID-19 patients, we included all inpatients treated with chloroquine for COVID-19 in the Spaarne Gasthuis (Haarlem/Hoofddorp, the Netherlands) and had an ECG performed both in the 72 h before and during or at least 48 h after treatment. We analyzed the (change in) QRS and QTc interval using the one-sample t-test. Of the 106 patients treated with chloroquine, 70 met the inclusion criteria. The average change in QRS interval was 6.0 ms (95% CI 3.3-8.7) and the average change in QTc interval was 32.6 ms (95% CI 24.9-40.2) corrected with the Bazett's formula and 38.1 ms (95% CI 30.4-45.9) corrected with the Fridericia's formula. In 19 of the 70 patients (27%), the QTc interval was above 500 ms after start of chloroquine treatment or the change in QTc interval was more than 60 ms. A heart rate above 90 bpm, renal dysfunction, and a QTc interval below 450 ms were risk factors for QTc interval prolongation. Chloroquine prolongs the QTc interval in a substantial number of patients, potentially causing rhythm disturbances. Since there is no substantial evidence for a beneficial effect of chloroquine, these results discourage its use in COVID-19 patients. |*COVID-19 Drug Treatment[MESH] |Aged[MESH] |COVID-19/*epidemiology/physiopathology[MESH] |Chloroquine/*adverse effects[MESH] |Cohort Studies[MESH] |Electrocardiography/*drug effects/trends[MESH] |Female[MESH] |Heart Rate/drug effects/physiology[MESH] |Humans[MESH] |Long QT Syndrome/*chemically induced/*epidemiology/physiopathology[MESH] |Male[MESH] |Middle Aged[MESH] |Netherlands/epidemiology[MESH]QTc Prolongation in COVID-19 Patients Using Chloroquine (epmc).pdf DeepDyve Pubget Overpricing